Dendritic cell-mediated cancer immunotherapy with Ecklonia cava fucoidan

Int J Biol Macromol. 2020 Sep 15:159:941-947. doi: 10.1016/j.ijbiomac.2020.05.160. Epub 2020 May 21.

Abstract

Fucoidan is known to exert immunomodulatory effects in animals and humans. Here, we extracted fucoidan from Ecklonia cava (ECF) and evaluated its immunostimulatory and anticancer activities in mice. Treatment with ECF resulted in the activation of bone marrow-derived dendritic cells (BMDCs) in vitro and splenic DCs in vivo. Moreover, the combination of ECF and ovalbumin (OVA) promoted OVA-specific T cell proliferation and cytokine production, which consequently suppressed B16-OVA tumor growth in vivo. The combination treatment with ECF and carcinoma self-antigen resulted in the inhibition of the growth of CT-26 carcinoma in mice through carcinoma antigen-specific immunity. Thus, ECF could function as an adjuvant for the induction of anticancer immunity.

Keywords: Anti-cancer; Dendritic cell; Ecklonia cava Fucoidan.

MeSH terms

  • Animals
  • Antigens, Neoplasm / immunology
  • Cytokines / metabolism
  • Dendritic Cells / drug effects*
  • Dendritic Cells / immunology*
  • Dendritic Cells / metabolism
  • Disease Models, Animal
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Immunotherapy* / methods
  • Melanoma, Experimental
  • Mice
  • Mice, Transgenic
  • Neoplasms / etiology*
  • Neoplasms / metabolism*
  • Neoplasms / therapy
  • Phaeophyceae / chemistry*
  • Polysaccharides / pharmacology*
  • Spectroscopy, Fourier Transform Infrared
  • Treatment Outcome

Substances

  • Antigens, Neoplasm
  • Cytokines
  • Polysaccharides
  • fucoidan